Castle Creek Biosciences Inc., a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options, has formed a new research collaboration with Mayo Clinic. The partnership was forged under the leadership of Castle Creek President and CEO, Mathew Gantz, and direction from Founder and Chairman Jeff Aronin. Leveraging the clinical development expertise of cellular and genetic technology developed by Castle Creek, Mayo Clinic principal investigator, David R. Deyle, M.D., a board-certified geneticist and nationally recognized medical expert in connective tissue disorders,
The post Castle Creek Biosciences Collaborates with Mayo Clinic to Expand Gene Therapy Platform appeared first on Pharma Mirror Magazine.
